Nonpartisan civic infrastructure
AllCiv·Legis1
·

S. 3974

BillFederalSenateIntroduced
To prohibit the consideration of patients' race, color, religion, sex, national origin, age, disability, vaccination status, veteran status, or political ideology or speech in determining eligibility for monoclonal antibody doses distributed by the Federal Government.
About This Bill
Introduced
Congress
117th (2021–2023)
Introduced
March 31, 2022
Cosponsors (0)
None
View PDF ↗

Summary

Highlight any text to annotate
Ending Discrimination in COVID-19 Treatments Act This bill prohibits consideration of certain factors, including vaccination status, in decisions about an individual's access to federally provided monoclonal antibody therapies to treat COVID-19. As a condition of receiving the therapies from the federal government, states must ensure that providers do not consider specified demographic characteristics, veteran status, or political ideology or speech when determining a patient's eligibility for such therapies.

Take Action

Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.